The table indicates that current breast cancer clinical trials are focused on the therapeutic effects of nab-paclitaxel combined with new drugs with different mechanisms for treating breast cancer with different molecular types, such as the tyrosine kinase inhibitor pyrotinib and the anti-PD-L1 monoclonal antibody SHR-1316. This evidence concerns the gene CD274 and breast carcinoma.